Mixed results for Moderna mRNA flu vaccine trial / Photo: Maddie Meyer - GETTY IMAGES/AFP
-
Capuozzo grabs hat-trick as Toulouse win Champions Cup opener
-
Emotional Norris triumph prompts widespread affection and respect
-
Louvre says hundreds of works damaged by water leak
-
UN calls on Taliban to lift ban on Afghan women in its offices
-
Rutter rescues Brighton in West Ham draw
-
England trained 'too much' prior to Ashes collapse, says McCullum
-
How Lando Norris won the F1 title
-
Tearful Norris completes 'long journey' to become F1 world champion
-
'It's all over': how Iran abandoned Assad to his fate days before fall
-
Lando Norris: England's F1 prince charming with a ruthless streak
-
Lando Norris crowned Formula One world champion
-
What next for Salah and Liverpool after explosive outburst?
-
Netanyahu expects to move to Gaza truce second phase soon
-
Nervous Norwegian winner Reitan overshadows Hovland in Sun City
-
Benin government says 'foiled' coup attempt
-
British photographer Martin Parr dies aged 73: Foundation
-
Benin govt says 'foiled' coup attempt
-
Stokes refuses to give up hope as Ashes ambitions hang by thread
-
'Good banter': Smith and Archer clash in Gabba Ashes Test
-
Sri Lanka issues landslide warnings as cyclone toll hits 627
-
Macron threatens China with tariffs over trade surplus
-
Palestinian coach gets hope, advice from mum in Gaza tent
-
Undercooked, arrogant? Beaten England's Ashes build-up under scrutiny
-
Benin presidency says still in control despite coup attempt
-
In Jerusalem, Merz reaffirms Germany's support for Israel
-
Australia crush England by eight wickets for 2-0 Ashes lead
-
Star UK chef redesigns menu for dieters on skinny jabs
-
Australia on brink of victory at Gabba for 2-0 Ashes lead
-
South Africa coach Conrad says meant no malice with 'grovel' remark
-
Neergaard-Petersen edges out Smith for maiden DP World Tour win
-
Stokes and Jacks lead rearguard action to keep England alive
-
Sri Lanka issues landslide warnings as cyclone toll hits 618
-
McIlroy going to enjoy 'a few wines' to reflect on 'unbelievable year'
-
India nightclub fire kills 25 in Goa
-
Hong Kong heads to the polls after deadly fire
-
Harden moves to 10th on NBA all-time scoring list in Clippers defeat
-
Number's up: Calculators hold out against AI
-
McIntosh, Marchand close US Open with 200m fly victories
-
Divided US Fed set for contentious interest rate meeting
-
India nightclub fire kills 23 in Goa
-
France's Ugo Bienvenu ready to take animated 'Arco' to Oscars
-
Trump's Pentagon chief under fire as scandals mount
-
England's Archer takes pillow to second Ashes Test in 'shocking look'
-
Australia skipper Cummins 'good to go' for Adelaide Test
-
IBC Advanced Alloys Reports Results from its 2025 Annual General Meeting
-
5 Foods and Habits That Can Reverse Teeth Whitening Results
-
Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science
-
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
-
Mexico's Sheinbaum holds huge rally following major protests
-
Salah tirade adds to Slot's troubles during Liverpool slump
NYSE - LSE
| RBGPF | 0% | 78.35 | $ | |
| RIO | -0.92% | 73.06 | $ | |
| CMSC | -0.21% | 23.43 | $ | |
| NGG | -0.66% | 75.41 | $ | |
| GSK | -0.33% | 48.41 | $ | |
| AZN | 0.17% | 90.18 | $ | |
| BTI | -1.81% | 57.01 | $ | |
| RELX | -0.55% | 40.32 | $ | |
| CMSD | -0.3% | 23.25 | $ | |
| SCS | -0.56% | 16.14 | $ | |
| RYCEF | -0.34% | 14.62 | $ | |
| VOD | -1.31% | 12.47 | $ | |
| BCC | -1.66% | 73.05 | $ | |
| JRI | 0.29% | 13.79 | $ | |
| BCE | 1.4% | 23.55 | $ | |
| BP | -3.91% | 35.83 | $ |
Mixed results for Moderna mRNA flu vaccine trial
US biotech company Moderna said Thursday it had mixed results from a large-scale trial of its mRNA flu shot, based on the same technology used in its successful Covid-19 vaccine.
Moderna's experimental mRNA-1010 flu shot is "quadrivalent," meaning it targets four strains of flu: A/H1N1, A/H3N2, B/Yamagata and B/Victoria -- selected based on recommendations by the World Health Organization (WHO).
The Massachusetts-based company said that its flu shot generated an immune response against influenza A strains that was equal or superior to that of already licensed vaccines.
However, it fell short of the already approved vaccines against strains of the less-common influenza B, Moderna said in a statement.
"Today's results represent an important step forward in the development of mRNA-based influenza vaccines," Moderna president Stephen Hoge said.
"We have already updated the vaccine that we believe could improve immune responses against influenza B and will seek to quickly confirm those improvements in an upcoming clinical study."
The Phase 3 trial of the mRNA shot involved 6,102 adults in Argentina, Australia, Colombia, Panama, and the Philippines during the Southern Hemisphere influenza season.
Participants received a single dose of mRNA-1010 or a single dose of a licensed influenza vaccine.
Moderna said 70 percent of the mRNA-1010 recipients reported adverse reactions such as headaches, swelling and fatigue compared to 48 percent in the other group.
Virus strains have to be selected six to nine months before the vaccines are intended to be used, and their efficacy is approximately 40 to 60 percent.
Moderna is simultaneously conducting an efficacy trial of its vaccine.
Moderna and other vaccine manufacturers, including Sanofi, hope that mRNA technology -- which provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells -- can accelerate immunization development and production, and heighten efficacy.
There are some three to five million severe influenza cases annually worldwide and between 290,000 and 650,000 deaths, the WHO says.
Moderna's stock price was down more than six percent in after-hours trading in New York.
E.Rodriguez--AT
